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Environmental exposures to low levels of
airborne chemicals have been associated with
adverse symptoms in susceptible persons, even
though such exposures are tolerated by the
majority of the population without adverse
reaction (1). A wide variety of controversial
labels have been applied to the conditions of
such chemically sensitive patients, including
multiple chemical sensitivities (MCS), envi-
ronmental illness, idiopathic environmental
intolerance, chemical hypersensitivity syn-
drome, chemical intolerance, twentieth cen-
tury disease, and odor intolerance, among
others (2–4). Contemporary conditions that
may overlap with or include components of
chemical sensitivity (CS) include sick building
syndrome, fibromyalgia, chronic fatigue
syndrome, and Gulf War illness (5–8).
Symptoms reported by chemically sensi-
tive patients upon exposure typically involve
multiple organ systems and may include
headache, fatigue, difficulty concentrating,
depression, dyspnea, cough, nasal conges-
tion, muscle and joint pain, nausea, dizzi-
ness, abdominal pain, and paresthesias. In
view of the diffuse symptom constellation
and the lack of an accepted, identifiable
mechanism linking symptom to exposure,
the nature (and even existence) of these
conditions has been the subject of much
controversy within scientific (2,9–13), regu-
latory (12,14,15), social (16,17), and judi-
cial (18) arenas. Whether or not these
symptoms ultimately have somatic or psy-
chosomatic etiology, the experience and
consequences for the affected individuals
are very real. Among these chemically sensi-
tive individuals, alterations in lifestyle may
result from self-treatment through active
avoidance of perceived triggering chemi-
cals; in some cases, significant disability
may follow (15,19–23).
Nomenclature and definitions are
difficult when individual responses to envi-
ronmental chemical stimuli fall short of easily
recognizable disease end points (24,25), and a
plethora of definitions relating to different
facets of the phenomenon of CS have
appeared in the literature (4,19–21,25–30).
Here we will use the general term “chemical
sensitivity” (CS) to describe individuals who
report the development of symptoms upon
exposure to various airborne stimuli but who
may or may not perceive themselves to be
chronically ill as a result of those symptoms
and may or may not have sought health care
for their alleviation. The term “multiple
chemical sensitivities” (MCS) will refer to
individuals who perceive themselves as ill and
meet the criteria originally proposed by
Cullen in 1987 (26). Thus, CS will include
the entire spectrum of the phenomenon,
ranging from odor intolerance and cacosmia
to building-related illness and MCS.
Although considerable attention and
debate have focused in recent years on the
MCS subset (21,24), the general phenome-
non of CS may be viewed in a broader con-
text. Thus, the excess of adverse symptoms
reported among communities located near
toxic waste sites or sources of air pollution, or
after chemical spills or accidental industrial
chemical releases (10,31), as well as health
complaints from workers in buildings [e.g.,
U.S. Environmental Protection Agency
employees exposed to outgassing from new
carpet (32)], from groups claiming sensitivity
to particular gasoline additives [e.g., methyl
tert-butyl ether (33)], from communities
exposed to pesticide spraying (34) or wood
preservatives (35), or from veterans of the
Persian Gulf War (5,6) may all represent dif-
ferent expressions of a general, but poorly
understood, mechanism of toxicity. That spe-
cific mechanisms by which low levels of air-
borne chemicals may physically interact with
the body and produce symptoms have not yet
been elucidated does not mean such mecha-
nisms are unlikely to be defined but rather
that they may not be easily categorized into
currently understood pathways of disease and
pathology. The common, but by no means
universal, ﬁnding of psychiatric co-morbidity
has led to controversy regarding appropriate
diagnostic and therapeutic approaches for
these patients (23,36).
As with any illness, whether perceived or
clinically accepted, the relevance of CS to the
public interest depends in part on the preva-
lence or incidence of the condition. Until
recently, the epidemiology of CS was poorly
characterized, but studies completed within
the last few years suggest that CS, in its vari-
ous forms, may be much more common than
previously recognized. In a survey of 643
undergraduate college students, Bell et al.
(20) found that 66% reported feeling moder-
ately to markedly ill after exposure to low lev-
els of at least one of five common
environmental odors: pesticide, car exhaust,
drying paint, new carpet, and perfume. Some
15% reported similar reactions to at least four
of these exposures. In a larger prevalence
study, Meggs et al. (37) reported results from
a population-based telephone survey in rural
North Carolina: some 33% of 1,027 individ-
uals polled reported CS, comparable to the
percentage reporting allergy. Recently, a land-
mark article by Kreutzer et al. (38) described
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Unexplained Symptoms
Environmental exposures to very low levels of airborne chemicals are associated with adverse
symptoms, often affecting multiple organ systems, in the phenomenon of chemical sensitivity
(CS). Recent surveys suggest a signiﬁcant prevalence of chemically sensitive subjects in the United
States, but the mechanism linking exposure to symptoms remains unclear, despite the advance-
ment of a variety of theoretical models. In many of these models, exposure of the nasal respiratory
system to an airborne agent is the ﬁrst step in the pathway leading to symptoms. In this article, we
advance the hypothesis that interactions between environmental chemicals and the vomeronasal
organ (VNO) may play a role in the etiology of CS. The VNO, a bilateral, tubular organ located
in the nose, serves in animals as part of a sensitive chemosensory system; however, evidence sug-
gesting that the VNO retains a functional role in the adult human is controversial. Reported char-
acteristics of the human VNO relevant to CS, including location, prevalence, selective sensitivity
to airborne chemical exposure, and capacity to produce systemic effects, are discussed within the
context of this ongoing debate. Beyond relevance to CS, the demonstration of an active, adult
VNO could have signiﬁcant impact on environmental toxicology. Key words: chemical intolerance,
chemical sensitivity, environmental intolerance, MCS, multiple chemical sensitivities, VNO,
vomeronasal organ. Environ Health Perspect 110(suppl 4):655–661 (2002).
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data from a rigorously conducted telephone
survey of more than 4,000 Californians.
Some 6.3% reported a prior formal diagnosis
of MCS or environmental illness by a doctor,
and nearly 16% reported being “allergic or
unusually sensitive” to everyday chemicals. In
addition, the results showed surprising homo-
geneity across income, employment, and
educational levels.
Although case definitions in each study
differed (and the Kreutzer study did not
include a specific definition), the above
results suggest that both self- and physician-
diagnosed chemical sensitivity are common
phenomena in the United States. Rising pub-
lic awareness of CS, regardless of etiology or
demonstration of causality, may ultimately
provide another source of input to the devel-
opment and implementation of regulatory
policy. If low-level chemical exposures are
eventually recognized to be causally related to
adverse health effects in some sensitive subset
of the population, even if manifested only as
undesired symptoms, then adjustment of
environmental policy and regulatory limits to
accommodate those individuals, with poten-
tially enormous economic impact, will need
to be considered at a societal level (15,16).
Current Theories of Chemical
Sensitivity
In chemically sensitive subjects, symptoms are
reported at exposure levels well below those
associated with known toxicologic mecha-
nisms. The etiology of symptom production
in these patients is a subject of continuing
controversy and speculation (1,19,39), and no
consensus has yet been reached. A variety of
different models and theories have been pro-
posed to account for various facets of the phe-
nomenon of CS; representative examples are
brieﬂy highlighted here.
The olfactory-limbic kindling model
invokes the concept of “subconvulsive chem-
ical kindling” (a form of time-dependent
sensitization) in the olfactory bulbs and vari-
ous regions of the brain to explain develop-
ment of sensitivity to chemicals seen in some
subjects after repeated, low-level environ-
mental exposures (40). The theory invokes a
two-step process, beginning with initiation,
in which repeated, intermittent exposures, or
a single, intense exposure of the nose acts to
produce some form of alteration of olfactory-
limbic neural pathways. Subsequently, in the
elucidation phase, exposure of the chemical
agent to the nose provokes an amplified
neural response, ultimately leading to
production of symptoms.
Another model proposes that CS arises
from neurogenic inﬂammation, a process that
might begin with an irritant molecule bind-
ing to sensory nerve C-ﬁbers (41) in the skin
and mucous membranes, triggering the
release of substance P and other mediators of
inﬂammation that may act locally or systemi-
cally to account for the varied patterns of
symptom presentation in patients with CS.
Both the oropharyngeal mucosa (42) and res-
piratory mucosa(43) have been cited as possi-
ble initial targets for chemical triggers in
variants of this model.
The theory of toxicant-induced loss of
tolerance seeks to address CS within a toxico-
logic framework and also involves two phases:
initial exposure to a chemical, causing a loss
of tolerance by susceptible individuals, fol-
lowed by heightened responses (44). The
concept of “masking” is also invoked, in
which chronic exposures to multiple trigger-
ing agents in the environment may blunt the
symptom response observed in single-
challenge laboratory investigations.
Classical conditioning on olfactory stim-
uli has also been suggested as an explanation
for CS (45–47). Van den Bergh et al. (48)
have recently reported acquisition and extinc-
tion of somatic symptoms in response to
odors using a classical Pavlovian paradigm.
Some studies have found that subjects pre-
senting with CS have an elevated frequency of
co-existing Axis I psychiatric diagnoses, such
as depression, anxiety, and somatoform disor-
ders (19). In one study, there was a greater
prevalence of somatization symptoms in MCS
patients before the onset of the condition,
compared with controls (49), suggesting that
some form of psychological vulnerability may
play a role in susceptibility to the condition.
Case reports in which traumatic over-
exposure to a toxic gas was subsequently fol-
lowed by typical symptoms of panic on
re-exposure to low levels of that gas were cited
by Shusterman (10) as examples of behavioral
sensitization to irritants or odorants. Similar
symptoms on exposure to solvent vapors have
also been described in workers who did not
have identifiable prior traumatic overexpo-
sures, and the general phenomenon has been
termed “odor-induced panic attack” (50).
The diversity of these models and the
overall scarcity of experimental data with
which to assess their validity highlight the
need to broaden the search for readily testable
mechanisms of action that may underlie the
phenomenon of CS, as well as the need for
objective clinical studies. Interactions in the
nasal airway are an integral part of several of
the above theories of CS. However, a role for
the nose and the specific mechanisms that
might be involved in the pathogenesis of CS
have not yet been experimentally demon-
strated. It is the purpose of this article to pro-
pose another potential mechanism involving
the nasal airway that might be involved in the
etiology of CS, namely, interactions between
environmental chemicals and the vomeronasal
organ (VNO).
The Vomeronasal Organ
The VNO, also referred to as Jacobson’s
organ, is a bilateral, tubular structure that is
located in the nose and has been well studied
in a variety of animal species, with apparent
sensory functions permitting various forms of
chemical communication that may elicit
innate reproductive and social behaviors as
well as neuroendocrine changes (51). The
organ is thought to be the site of reception
involved in signaling between animals via nat-
urally secreted, putative airborne pheromones
(52,53).Indeed, a gene family encoding likely
pheromone receptors in the rat VNO has
been identiﬁed (54). First reported in an adult
human by Ruysch (55) in 1703, further
description of this organ in animals was pre-
sented by Jacobson (56) in 1811, and in adult
humans by Potiquet (57) in 1891. Although
the VNO is clearly present in the human fetus,
publications during the early part of the 20th
century suggested that the organ was atrophic
or vestigial in adults (58); contemporary text-
books of human anatomy still generally omit a
description of the VNO. During the last 15
years, however, a signiﬁcant and largely unrec-
ognized body of literature has emerged, some
of which suggests that this organ may be pre-
sent in adult humans and that it may retain an
active, functional role, at least in some individ-
uals. Comprehensive reviews of the work sup-
porting these concepts have been published by
Monti-Bloch et al. (59,60).
Nevertheless, the notion of a present and
functional VNO in humans remains contro-
versial, and some polarization of the scientiﬁc
literature is apparent. A recent review devoted
a single paragraph to the human VNO and
concluded that “the overwhelming evidence
would therefore not support a human VNO
that is functional in any meaningful way”
(61). The comments in that paragraph, how-
ever, did not appear to have addressed the
content of papers cited in the same review
that arrived at different conclusions. To our
knowledge, the primary published evidence
pointing to a functional human VNO has
never been directly refuted in a published,
experimental study. It is possible that some
elements of this ongoing controversy lie out-
side the bounds of simple, rational, scientiﬁc
assessment. Below, we brieﬂy summarize the
results of some important prior studies
addressing the structure, prevalence, activity,
and function of the VNO in adult humans.
Structure of the VNO
In the adult human, the VNO has been
described as a pair of blind-ended tubes or
ducts, typically 2–10 mm long, one per nos-
tril, oriented in an anterior–posterior direc-
tion and located under the respiratory
mucosa lining each side of the nasal septum
(62). The VNO opens into the nasal cavity
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through a round or oval depression or “pit”
in the mucosa, which is typically 0.2–2 mm
in largest diameter. The VNO pit has been
described as being found in the anterior, infe-
rior region of the septum, several millimeters
above the ﬂoor of the nasal cavity and some
1–3 cm posterior to the posterior margin of
the external naris, near the junction of the
septal cartilage and bony septum (58,59).
Most prior studies of gross morphology of
the human VNO have used cadavers or tissue
excised during surgery. However, several
recent studies have used modern imaging
techniques, for the first time, to study the
structure of the VNO in living humans.
Trotier et al. (63) instilled a contrast agent
into seven VNO pits and used helical com-
puted tomography to image the associated
ducts. Lengths of the ducts were found to
range from 2 to 5.7 mm.
In a study by Abolmaali et al. (64), the
VNO ducts of 15 subjects with pit diameters
of at least 1 mm were infused with a contrast
agent, and the ducts were visualized with
magnetic resonance imaging. The median
duct length was 7 mm, although the shapes
and sizes exhibited signiﬁcant variation (range
of lengths, 3–47 mm). The VNO opening
was located at a mean distance of about 25
mm from the columella and 9 mm above the
floor of the nasal cavity. Of note, the duct
was found to cross to the contralateral side of
the septum in one case.
The unique ultrastructure of the human
VNO has also been described by several
authors (58,62,65). The tubular organ is
lined with a pseudostratified, columnar
epithelium that includes at least three mor-
phologically distinct cell types (62). One
unusual cell type found on the medial wall of
the human VNO, the “light cell” (62) or
“microvillar cell” (65), has an apical surface
with short microvillar projections and a basal
surface that narrows to a thin, axonlike process
reaching the basement membrane. Recent
experiments, including isolated, whole-cell
recordings, have suggested that these cells may
be electrically active neurosensory cells with
apical receptors activated by binding of natu-
rally occurring pheromones or synthetic
analogs [termed “vomeropherins” by Monti-
Bloch and colleagues (59,66)]. In one study,
these cells were found to stain with immuno-
cytochemical neuronal markers (67). In other
studies, however, antibodies against olfactory
marker protein, found in neuronal cells associ-
ated with the VNO in some animals, did not
stain human VNO epithelial cells (63).
In rodents, tracer studies have demon-
strated that the VNO forms one part of a
complete neurosensory system, which
includes receptor cells that communicate with
a nerve that follows the olfactory tracts
through the cribiform plate and projects to
the glomerular layer of the accessory olfactory
bulb (68). In humans, however, a complete
neural connection from the VNO to the
brain has not been morphologically demon-
strated, and this remains a significant criti-
cism of the hypothesis of a functional human
VNO. In addition, the accessory olfactory
bulb, although present in the human fetus, is
not thought to be present in the adult human
brain. However, numerous, small, unmyeli-
nated nerve ﬁbers have been reported in the
lamina propria surrounding the human
VNO, and it has been hypothesized that
these fibers may participate in communicat-
ing signals from the VNO to the central ner-
vous system (CNS) (59). Several functional
lines of evidence, discussed below, suggest
that such a connection should not be ruled
out and that excitation of the VNO by air-
borne chemicals may cause neurally mediated
changes in physiology and behavior.
Prevalence of the VNO
A number of studies have examined the
prevalence of the VNO in adult humans, as
identiﬁed by observation of the nasal opening
of the organ (the VNO pit). An early study
by Johnson et al. (58) found at least one
VNO pit in 39% of 100 adults; examinations
were conducted with the naked eye, without
magniﬁcation. Moran et al. (62) described a
study of 200 adults with examinations con-
ducted using a 40× binocular operating
microscope. Bilateral VNO pits were
observed in all 200 subjects, and the authors
remarked that a number of the pits would not
have been visible without magnification.
Stensaas et al. (65) reported that VNO pits
were identified in 93% of 410 consecutive
patients examined for potential nasal plastic
surgery and that those in whom pits were not
found had structural abnormalities of the
nasal septum. In a large study, Garcia-Velasco
and Mondragon (69) examined 1,000 adult
candidates for rhinoplasty and identified
VNO pits in 91% (in 102 patients, the pits
were not observed until after surgical correc-
tion of septal deviation). The prevalence of
the pits was about equal in males and females.
These data suggest that the VNO pit is pre-
sent in most adult humans and that examina-
tion under magnification is important for
identiﬁcation of smaller pits (70).
However, two new studies have reported
lower prevalence of the VNO. Trotier et al.
(63) performed endoscopic examination of
1,842 patients without nasal septal pathology
and, during initial examination, found a
VNO pit on at least one side in 26% of sub-
jects. Surprisingly, repeated observations on
the same subjects, with time intervals ranging
from days to months, revealed considerable
variability in the observation of the pits
(which were classified as well defined,
putative, or not present). Of well-deﬁned pits
at ﬁrst observation, nearly 13% became puta-
tive and another 13% were not present at sec-
ond observation. The cause underlying this
significant variation in VNO observations
was not clear.
In a recent study by Zbar et al. (71), 253
subjects were examined using a nasal specu-
lum without magnification, followed by
examination with an endoscope or with a 6×
operating microscope if a VNO pit was not
initially identified. In this study, a pit was
defined as associated with a VNO if it was
located within prescribed boundaries: 1–3
mm above the ﬂoor of the nasal septum and
1–2 cm posterior to the cutaneous aspect of
the columella. Using this definition, the
VNO prevalence was only 6%.
Finally, an important and recent anatomi-
cal study by Jacob et al. (72) calls into ques-
tion the validity of adult human VNO
identification in numerous prior studies,
through description and characterization of
the location and appearance of another little-
known structure, the nasopalatine duct
(NPD). In some animals, this structure pro-
vides direct connection between the oral and
nasal cavities and in some cases is associated
with the VNO system. In a study of 221
human subject nostrils, a structure identiﬁed
as the NPD was identified in 94%; in an
associated cadaver study (n = 8), the NPD
was found in 100% and was bilateral in all.
The authors conclude that “Unusually con-
tradictory anatomical descriptions in the
human putative VNO literature may be
attributable to inexact descriptions or
misidentification of structures” (72). If fur-
ther work verifies that prior studies have
indeed confused the VNO and the NPD,
then the prevalence of the VNO as well as the
balance of evidence supporting, and arguing
against a functional role for this organ will
need to be reassessed.
Electrical Activity of the VNO
Some of the most intriguing evidence in favor
of the VNO as an active sensory system in
humans comes from studies of the electrical
activity of the VNO epithelium by Monti-
Bloch and colleagues (73,74), using a minia-
ture, triaxial probe (75). In these experiments,
the center conductor of the probe was placed
in the VNO pit of a subject, in contact with
the mucosal surface. The inner, hollow, coax-
ial sheath was connected to pulsed, gas deliv-
ery system and provided discrete puffs of test
gases at the VNO opening. The outer, hollow
sheath was connected to a suction source and
acted to scavenge the gas puff, preventing dif-
fusion of the test compound into the olfac-
tory cleft or the nasopharynx. The negative
mucosal electrical potential elicited in
response to a gas puff, measured with respect
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termed the “electrovomerogram” (74), by
analogy with the electro-olfactogram similarly
obtained at the olfactory mucosa (76).
Patients tolerated the procedure well and
reported no olfactory sensations during the
gas puffs.
In experiments reported by Monti-Bloch
and Grosser (74), on adult subjects, gas puffs
containing 15–25 pg of putative human
pheromones were applied to the VNO, in a
humidified air stream, using pulses of
0.1–1.0 sec in duration; control puffs con-
tained olfactory test stimuli, such as clove oil,
or diluent alone. In response to pheromone
puffs, typical depolarizations of 4 mV were
observed, which subsequently decayed over a
time course of several seconds (73). Much
smaller depolarizations resulted from puffs
with diluent alone or with olfactory stimu-
lants. In contrast, when the probe was located
on the olfactory mucosa, the olfactory stimu-
lants produced large depolarizations, whereas
the putative pheromones produced much
weaker responses. Further experiments demon-
strated a sigmoidal dose–response curve and
compound-speciﬁc adaptation.
The mucosal electrical potential response
was shown to be speciﬁc to the VNO pit, and
not a general characteristic of the nasal respi-
ratory mucosa, through a series of experi-
ments in which the probe was sequentially
moved along the mucosa, away from the
VNO pit, with diminishing response to test
puffs (73). These results suggest that the
VNO mucosa generates a receptor potential
in response to stimulation with extremely
small amounts of speciﬁc chemicals, and that
the olfactory and VNO sensory mucosa have
different chemical speciﬁcities. Although not
demonstrating the transmission of this sen-
sory receptor potential to the CNS, or even
beyond the local region of the VNO, these
data are consistent with the concept of an
active VNO sensory epithelium in adult
humans. Gender-speciﬁc responses were also
observed with different putative pheromones
(73,74). In assessing this work, however, it
should be noted that experimental studies
confirming (or refuting) the sensitivity and
specificity of the VNO mucosal potential
response to test exposures have not been
published by any other group.
Evidence for a Functional VNO–CNS
Connection
Double-blinded, placebo-controlled, random-
ized trials reported by Berliner et al. (77) have
presented initial (although nonanatomical)
evidence for a functional neural pathway con-
necting the VNO with pituitary and hypo-
thalamic regions of the brain. In particular,
subjects were exposed nasally to 1-sec pulses
of a particular synthetic steroidal compound
(pregna-4,20-diene-3,6-dione, or PDD), or
to a control substance, every 10 min during a
6-hr period. The total amount of PDD deliv-
ered to a subject during the course of the
experiment was about 10 ng. Statistically sig-
niﬁcant decrements in measures of luteinizing
hormone (LH) pulsatility and LH plasma lev-
els and of follicle-stimulating hormone pul-
satility were observed (p < 0.05), but only in
males exposed to PDD. In addition, signifi-
cant changes (with short latencies) were
observed, after the individual puffs of PDD,
in measures of autonomic function including
heart rate, respiratory rate, skin conductance,
and indices of brainwave activity. Additional
control experiments included application of
the gas puff to the nasal respiratory and olfac-
tory mucosa and revealed no significant
changes in hormone levels or autonomic
function. The authors concluded that these
data support the concept of an active
VNO–hypothalamic–pituitary neural axis
(although without any known anatomical
correlates), and they pointed out a variety of
potential therapeutic uses for VNO stimu-
lants that might affect hypothalamic func-
tion, ranging from treatment of anxiety and
other CNS disorders to hormone replacement
therapy (78). In a different study that is
consistent with this idea, although not spe-
cific to the VNO, Stern and McClintock
(79), following earlier work by Cutler, Preti,
and colleagues (80,81), showed that con-
sciously undetected compounds (purported
pheromones), when applied to the upper lip
and presumably inhaled nasally, altered
reproductive cycles in women.
Recent studies by Sobel et al. (82) used
functional magnetic resonance imaging to
examine localized brain activity in response to
nasal exposure to a particular airborne
vomeropherin (estratetraenyl acetate) that
had been shown in earlier studies (73) to
selectively activate the VNO but not the
olfactory system. Signiﬁcant brain activation
was observed, relative to control exposures,
primarily in the anterior medial thalamus and
inferior frontal gyrus, and there was evidence
for increasing activation with higher concen-
tration of the administered compound. At
low vomeropherin concentration, none of the
subjects were able to specifically detect the
compound consciously, or through forced-
choice paradigms, despite significant brain
activation. In another experiment using the
same test compound, local exposure of the
VNO resulted in cortical evoked potentials in
the temporal regions, with latencies that
could be consistent with involvement of a
polysynaptic neural pathway (59).
At a higher organizational level, changes
in human behavior and cognition arising
from exposure to purported VNO stimulants,
without olfactory recognition, have recently
been reported by Grosser et al. (83). In this
double-blinded, randomized study of 40
women, a vomeropherin (androstadienone)
in a diluent (propylene glycol), or a control
(the diluent alone), was locally applied to the
VNO for 1 sec in a vapor stream using a
miniature, coaxial probe. This probe was
apparently the same as that used in earlier
studies of VNO mucosal potentials (74), and
it also included a scavenging system intended
to prevent airborne diffusion of the applied
compounds beyond the local area of the
VNO pit. A modified version of a validated
neuropsychological questionnaire was filled
out before the start of each session and
45 min after exposure. A variety of auto-
nomic indicators [respiratory and cardiac
rates, galvanic skin response, body tempera-
ture, electroencephalogram (EEG)] were also
monitored before and after the exposure.
Statistically signiﬁcant reductions (p < 0.001)
in indices of overall negativity, negative affect,
and negative character were reported for the
experimental group. At 35 min postexposure,
significant changes in autonomic measures
were noted, including decrements in respira-
tory and cardiac rates and galvanic skin
response, and an increase in alpha-wave com-
ponent of the EEG; these differences became
insigniﬁcant at 75 min postexposure.
The study by Grosser et al. (83) provided
significant evidence that nasal exposure to
androstadienone, in a region localized around
the VNO opening, resulted in changes of
affect and of autonomic indices. The authors
concluded that activation of the VNO repre-
sented the first step in the mechanism of
action of androstadienone. Although the evi-
dence presented is consistent with this idea, a
stronger conclusion would have been reached
if another control experiment had been per-
formed in which regions of nasal mucosa
other than that near the VNO were exposed
to the pulse of androstadienone. Note also
that objective data demonstrating the efﬁcacy
of the vapor scavenging system has not been
published, and incomplete scavenging would
raise the possibility that other mechanisms,
such as direct absorption into the blood-
stream through the nasal mucosa, or periax-
onal transport along olfactory neurons into
the brain, could have contributed to the
observed results.
Potential Relation of the VNO
to Chemical Sensitivity
As a whole, the body of work cited above
suggests that nasal exposures to low levels of
certain natural or synthetic airborne chemi-
cals may alter CNS activity and function,
with resultant changes in behavior and physi-
ology, even in the absence of direct, conscious
awareness of the exposure. Limited but
intriguing evidence supports activation of the
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a sensory–cognitive–physiologic pathway
exists, mediated by the VNO, it would repre-
sent a candidate mechanism for the phenom-
enon of CS. Extremely low levels of putative
pheromones or synthetic vomeropherins have
been shown, in isolated studies, to affect both
the peripheral and central nervous systems;
similarly, exposure to very low levels of air-
borne chemicals are thought to produce
symptoms in chemically sensitive subjects.
The changes in autonomic function and
behavior that have been reported to result
from VNO exposure to vomeropherins
(59,84) are consistent with a potential role in
CS. If exposure of the VNO to certain com-
pounds (e.g., androstadienone) results in pos-
itive changes in affect, it is not unreasonable
to hypothesize that exposure to other com-
pounds might result in negative changes via a
similar pathway, contributing to expression of
the phenomenon of CS.
Differential sensitivity or prevalence of the
VNO among the population might then play
a role in determining susceptibility to mani-
festing CS. As a corollary, subpopulations
exhibiting dominantly positive changes in
affect and measures of well-being on exposure
to environmental chemicals might also exist,
but such individuals would be unlikely to
come to the attention of the health care sys-
tem as a result of such sensitivity. The true
prevalence of the VNO in adult humans is
clearly unknown, although recent estimates of
6–25% are similar to a recent estimate of the
prevalence of CS (16%). The suggestion by
Jacob et al. (72) that confusion between the
VNO and the NPD could be widespread in
the existing literature may require a critical re-
examination of much prior work in this area
and highlights the need for further well-
controlled experiments, but it does not dimin-
ish the possibility that patterns of differential
expression of the VNO may be identiﬁed.
Among many possible mechanisms, one
way in which the multi-organ system nature
of typical symptoms reported by chemically
sensitive subjects might arise is from alter-
ations in systemic hormone levels elicited by
VNO-mediated neuroendocrine activation.
As discussed above, prior studies have pre-
sented evidence linking VNO activation
with altered levels or temporal release pat-
terns of certain systemic hormones (77,84).
It is conceivable that other hormone levels
or patterns of release might be affected in an
analogous fashion.
In numerous studies, acute and chronic
changes in hormone levels have been associ-
ated with a broad range of symptoms, includ-
ing many that are reported in subjects with
CS. Potential CNS effects are legion (85),
and endocrine abnormalities are frequently
associated with disorders in behavior, mood,
and cognitive function (86). As examples,
chronic fatigue, anxiety, and emotional labil-
ity may be early symptoms arising from
hyperthyroidism. Transient hypomania may
be associated with the onset of thyroid hor-
mone replacement therapy in hypothyroid
patients. Anxiety and irritability are seen in up
to a third of patients with hyperparathy-
roidism, and fatigue, weakness, and depression
are also common. Alterations in sensory
thresholds to olfactory stimuli have been
reported in the hypoadrenal Addison’s patient;
acute mania may result when such a patient is
started on replacement corticosteroids.
Withdrawal of progesterone is thought to
precipitate depression in some women.
Many patients with CS complain of respi-
ratory symptoms; others complain of muscle
pain or nonspecific gastrointestinal symp-
toms. Changes in hormones mediated by the
hypothalamus could play a role in the etiol-
ogy of these symptoms as well. For example,
corticotropin-releasing hormone and proges-
terone are both respiratory stimulants,
whereas cyclic decreases in progesterone have
been associated with premenstrual exacerba-
tions of asthma (87). The onset of hyper-
thyroidism has been linked to increased
bronchial reactivity, and such patients may
also present with chronic or acute abdominal
pain that resolves on hormone replacement.
Hypothyroidism can be associated with spon-
taneous muscle cramps (of neural origin) and
muscle aches (from abnormal contraction and
relaxation) (88). Nonspeciﬁc abdominal pain
is also found in about a third of patients with
adrenal insufﬁciency (89).
Thus, we speculate that changes in levels
or temporal release patterns of a combina-
tion of systemic hormones, mediated by
VNO-stimulated neuroendocrine changes,
could potentially account for, or contribute
to, the diffuse symptomatology seen in sub-
jects with CS. To our knowledge, no sys-
tematic, controlled study of hormone levels
or temporal release patterns in such subjects
has yet been published.
Experimental Testing of the
Hypothesis
The hypothesis that a relationship exists
between the phenomenon of CS and the
VNO is amenable to experimental investiga-
tion. At the broadest level, previous anatomical
studies suggest that only a fraction of the
population has an identiﬁable, patent, VNO
duct. If the VNO is, in fact, a necessary part
of the pathway leading to CS, then the fre-
quency of identification of a patent VNO
duct would be expected to be considerably
higher in those with the condition than in
nonsensitive control subjects. Similarly, the
size of the VNO opening into the nasal cavity
may regulate exposure of the purported
neurosensory cells lining the VNO by
controlling diffusion of airborne chemicals
into the duct. If so, an association could be
expected between mean area (or other geo-
metric index) of the duct opening and the
presence or severity of CS. Standard statistical
techniques can be used to assess the strength
of such associations. Our laboratory has
recently begun a study of VNO prevalence
and morphology in chemically sensitive and
control subjects, with a goal of determining
whether differential expression and/or
structure of the VNO are correlated with the
diagnostic label of CS (90).
We plan further experimental tests, with
potential applications to treatment, that
include modiﬁcation of exposure of the VNO
in subjects with a diagnosis of CS. This
experimental approach uses a pool of subjects
with CS and an identiﬁable airborne exposure
previously determined to result in adverse
symptoms. In a clinical trial involving con-
trolled exposures to the specific airborne
agents, assessment of differences in symptom
reporting, with and without functional or
physical blocking of the VNO duct opening,
may provide evidence for or against involve-
ment of the VNO in the mechanism of CS.
Finally, our speculation concerning the
potential role of hormones in the mechanism
of CS can also be subjected to experimental
test. Speciﬁcally, the level and temporal release
patterns of candidate hormones could be
examined through blood assays in chemically
sensitive and normal subjects before and after
test exposures of the VNO to airborne agents.
Statistically signiﬁcant differences among the
groups in measures of pattern of hormone
release, such as peak levels, time-integrated
levels, or latencies, would support potential
involvement of systemic hormones in the eti-
ology of CS. Although associations alone do
not demonstrate causality, a positive result
from such a study would provide significant
impetus to focus attention on this pathway.
Summary
The phenomenon of sensitivity to low levels
of airborne, environmental chemicals is
increasingly recognized as a cause of morbid-
ity and economic loss in the United States,
with recent estimates suggesting that tens of
millions of people may be affected. The etiol-
ogy of symptom production in these subjects
is not understood and is the subject of con-
siderable controversy. A number of diverse
mechanisms and models have been proposed
to explain the symptoms associated with CS,
and initial interactions in the nasal respiratory
system are integral to many of these. To date,
there is no widely accepted mechanism of
action, and controlled studies designed to
evaluate the various theories have been scarce
and have yielded inconsistent results.
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with the VNO represents an intriguing candi-
date mechanism of toxicity in CS that has
been entirely unexplored. Although evidence
supporting functionality of the human VNO
is controversial, reported characteristics of the
VNO are relevant to the phenomenon of CS.
For example, although estimates of the preva-
lence of the VNO vary widely, figures from
recent publications are similar to a recent esti-
mate of the prevalence of CS. We speculate
that differential expression or sensitivity of
the VNO could play a role in determining
susceptibility to CS. In certain experiments,
the VNO has responded (at least locally) to
extremely small quantities of particular air-
borne chemicals, consistent with the very low
levels of exposure that trigger symptoms in
subjects with CS. Controlled human trials
have provided evidence that excitation of the
VNO may affect CNS-mediated functions,
observed as changes in indices of affect and in
patterns of hormone production. Among
many potential mechanisms, we hypothesize
that altered hormone release patterns could
contribute to the diffuse symptomatology
seen in subjects with CS.
Discovery that the VNO is integrally
involved in a pathway leading to CS could
foster the design of appropriate therapy to
reduce activation or exposure of this organ.
Because no therapy or intervention has thus
far been shown in controlled trials to be effec-
tive for chemically sensitive patients, the
demonstration of a therapeutic option would
be of considerable importance to this group.
The potential significance of an active
VNO extends far beyond work with the
chemically sensitive population. Should the
limited evidence discussed above be con-
firmed, then interaction of the VNO with
trace amounts of environmental airborne
chemicals may have a broad spectrum of
potential clinical consequences. Our intent
here is to bring the VNO, although little
known and controversial, to the attention of
the environmental health community.
Demonstration of an active, adult VNO could
be of great significance if linked to the phe-
nomenon of CS but would also potentially
open a new ﬁeld of environmental toxicology.
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